Health Care and Genomics Industry Veteran, Kathy Hibbs, Esq. Joins 23andMe as Chief Legal and Regulatory Officer

23andMe Builds Out Leadership Team with Recent Appointments of New Vice President of Product and a New Vice President of Business Development and Strategy

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--23andMe, the leading personal genetics company, today announced the appointment of Kathy Hibbs, Esq. as chief legal and regulatory officer. Hibbs brings more than 20 years of legal and management expertise in the clinical laboratory and medical device industries to 23andMe. Hibbs will oversee the legal and regulatory functions of the company. Prior to joining 23andMe, Hibbs served as senior vice president and general counsel, responsible for the legal, regulatory and business development functions at Genomic Health, Inc. Hibbs has also held related posts at Monogram Biosciences Inc., and Varian Medical Systems, Inc. Hibbs is active in several industry groups, including the American Clinical Laboratory Association (ACLA), the Coalition for 21st Century Medicine and the Personalized Medicine Coalition (PMC). Hibbs holds a Juris Doctorate from the University of California, Hastings School of Law and a Bachelor of Arts in political science from the University of California, Riverside.

"We have attracted incredible talent who share our passion for the company's mission of revolutionizing health care by empowering consumers with direct access to their genetic information."
"We are extremely pleased to have Kathy join our leadership team at this important time in our company's history," said Andy Page, president of 23andMe. "We are confident that Kathy's broad legal experience and diagnostic industry expertise will prove invaluable as we continue to enhance our service and expand our reach."

"23andMe is at the forefront of unlocking the power of genetics," said Kathy Hibbs, chief legal and regulatory officer for 23andMe. "I'm excited to join such a dynamic team at this pivotal point in the company's growth."

In addition, 23andMe has recently added top-tier talent to its leadership team with the appointment of Brad Kittredge as vice president of product and the appointment of Steve Schwartz as vice president of business development and strategy.

As vice president of product, Brad Kittredge is responsible for all elements of the 23andMe user experience, including product vision, design and management. Prior to joining 23andMe, Kittredge served as director of product management, health at Jawbone. Prior to his tenure at Jawbone, Kittredge held related positions at McKesson Corp. and was CEO and founder of ComplexDX. Kittredge holds an MBA from the Walter A. Haas School of Business; a master's in public health management, health policy from the University of California, Berkeley; a master's in international affairs from the University of California, San Diego; and a bachelor's degree in psychology from the University of California, Berkeley.

As vice president of business development & strategy, Steve Schwartz leads 23andMe's business development team, working with partners in life sciences, retail, academic medicine and health care. Schwartz is a health information technology veteran with more than 25 years of clinical laboratory, decision support and electronic health records industry experience. Before joining 23andMe, Schwartz was senior vice president of business development & strategy at Allscripts, a leading provider of electronic health records. Prior to Allscripts, Schwartz held related positions with Medifor Inc. and Laboratory Corporation of America Holdings (LabCorp). Schwartz holds degrees in business administration and psychology from the University of Washington.

"We are very excited about our recent hires and the growing management team at 23andMe," said Anne Wojcicki, co-founder and CEO of 23andMe. "We have attracted incredible talent who share our passion for the company's mission of revolutionizing health care by empowering consumers with direct access to their genetic information."

About 23andMe

23andMe, Inc. is the leading personal genetics company dedicated to helping individuals understand their own genetic information through DNA analysis technologies and web-based interactive tools. The company's Personal Genome Service® enables individuals to gain deeper insights into their ancestry and inherited traits. The vision for 23andMe is to personalize health care by making and supporting meaningful discoveries through genetic research. 23andMe, Inc., was founded in 2006, and the company is advised by a group of renowned experts in the fields of human genetics, bioinformatics and computer science. More information is available at


Kendra Cassillo, 415-658-9765
[email protected]
Paula Gitis, 415-946-1083
[email protected]

Suggested Articles

An inhaled drug developed by Aridis eradicated the novel coronavirus from infected hamsters at a much lower dose than other antibody treatments.

The financing positions SparingVision to fund clinical trials of an AAV gene therapy that could stop vision deterioration in 2 million patients.

The biotech behind AstraZeneca and the University of Oxford’s late-stage pandemic vaccine has hired Margaret (Meg) Marshall, M.D., as its new CMO.